Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
NGM707
DRUG
2 trials
Sponsors
Ngm Biopharmaceuticals Inc.
, NGM Biopharmaceuticals, Inc
Conditions
Advanced or Metastatic Solid Tumor Malignancies
Breast Cancer
Cervical Cancer
Cholangiocarcinoma
Colorectal Cancer
Endocervical Cancer
Esophageal Cancer
Gastric Cancer
+8 more
Phase 1
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Active, not recruiting
NCT04913337
NGM Biopharmaceuticals, Inc
Breast Cancer, Cervical Cancer, Cholangiocarcinoma +12
Start: 2021-06-09
End: 2025-07-31
Target: 179
Updated: 2024-10-02
Phase 2
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Completed
CTIS2022-503060-33-00
Ngm Biopharmaceuticals Inc.
Advanced or Metastatic Solid Tumor Malignancies
End: 2025-01-14
Target: 45
Updated: 2023-07-10
Related Papers
Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.
Journal of Clinical Oncology
2024-06-01
2 citations
Abstract CT099: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation
Cancer Research
2024-04-05
Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors
Cancer Research
2024-03-22